CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank33
3Y CAGR-14.1%
5Y CAGR-8.0%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-14.1%/yr
vs +3.0%/yr prior
5Y CAGR
-8.0%/yr
Recent deceleration
Acceleration
-17.0pp
Decelerating
Percentile
P33
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $98.06M | -13.3% |
| 2024 | $113.11M | +5.0% |
| 2023 | $107.70M | -30.3% |
| 2022 | $154.50M | +0.7% |
| 2021 | $153.35M | +2.9% |
| 2020 | $148.97M | -11.5% |
| 2019 | $168.38M | +22.6% |
| 2018 | $137.38M | +16.5% |
| 2017 | $117.88M | +58.0% |
| 2016 | $74.63M | - |